Ethical issues in nanomedicine: Tempest in a teapot?
Nanomedicine offers remarkable options for new therapeutic avenues. As methods in nanomedicine advance, ethical questions conjunctly arise. Nanomedicine is an exceptional niche in several aspects as it reflects risks and uncertainties not encountered in other areas of medical research or practice. Nanomedicine partially overlaps, partially interlocks and partially exceeds other medical disciplines. Some interpreters agree that advances in nanotechnology may pose varied ethical challenges, whilst others argue that these challenges are not new and that nanotechnology basically echoes recurrent bioethical dilemmas. The purpose of this article is to discuss some of the ethical issues related to nanomedicine and to reflect on the question whether nanomedicine generates ethical challenges of new and unique nature. Such a determination should have implications on regulatory processes and professional conducts and protocols in the future.
KeywordsEnhancement Ethics Nanomedicine Nanotechnology Risk Safety Social justice Uncertainty
- Beauchamp, T.L., and J.F. Childress. 2013. Principles of biomedical ethics, 7th ed. Oxford: Oxford University Press.Google Scholar
- Bennett, M.G., and R.J. Naranja Jr. 2013. Getting nano tattoos right—a checklist of legal and ethical hurdles for an emerging nanomedical technology. Nanomedicine 9(6): 729–731.Google Scholar
- British Medical Association. 2001. Research and experimentation on humans. In The medical profession & human rights. Handbook for a changing agenda, 205–240. London: Zed Books, Ltd.Google Scholar
- Davies, J.C. 2006. Managing the effects of nanotechnology. Woodrow Wilson Project on Emerging Nanotechnologies. Washington, D.C. http://www.nanotechproject.org/publications/archive/managing_effects_nanotechnology/. Accessed 4 Aug 2015.
- Drexler, K. Eric. 1986. Engines of creation: the coming era of nanotechnology. New York: Doubleday.Google Scholar
- FDA guidance to nanotechnology. http://www.fda.gov/ScienceResearch/SpecialTopics/Nanotechnology/default.htm.
- Geiser, M., B. Rothen-Rutishauser, N. Kapp, S. Schürch, W. Kreyling, H. Schulz, M. Semmler, V. Im Hof, J. Heyder, and P. Gehr. 2005. Ultrafine particles cross cellular membranes by nonphagocytic mechanisms in lungs and in cultured cells. Environmental Health Perspectives 113(11): 1555–1560.CrossRefGoogle Scholar
- Johnston, H., G. Pojana, S. Zuin, N.Raun Jacobsen, P. Moller, S. Loft, M. Semmler-Behnke, C. McGuiness, D. Balharry, A. Marcomini, H. Wallin, W. Krevling, K. Donaldson, L. Tran, and V. Stone. 2013. Engineered nanomaterial risk, lessons learnt from completed nanotoxicology studies: potential solutions to current and future challenges. Critical Reviews in Toxicology 43(1): 1–20.CrossRefGoogle Scholar
- Nanomedicine market—global industry analysis, size, share, growth, trends and forecast. 2013–2019. Transparency market research. http://www.transparencymarketresearch.com/pressrelease/nanomedicine-market.htm.
- Oberdörster, G., E. Oberdörster, and J. Oberdörster. 2005. Nanotoxicity: an emerging discipline evolving from studies of ultrafine particles. Environmental Health Perspectives 113(8): 23–39.Google Scholar
- Portnoy, E., B. Polyak, D. Inbar, G. Kenan, A. Rai, S.L. Wehrli, T.P. Roberts, A. Bishara, A. Mann, M. Shmuel, K. Rozovsky, G. Itzhak, T.B. Hur, S. Magdassi, D. Ekstein, and S. Eyal. 2016. Tracking inflammation in the epileptic rat brain by bi-functional fluorescent and magnetic nanoparticles. Nanomedicine (Ahead of print).Google Scholar
- Public Health Surveillance, the best weapon to avert epidemics. 2008. http://www.tree4health.org/distancelearning/sites/www.tree4health.org.distancelearning/files/readings/dcpp-surveillance.pdf.
- Rothman, S., and D. Rothman. 2003. The pursuit of perfection: the promise and perils of medical enhancement, 2003. New York: Pantheon Books.Google Scholar
- Sadrieh, N. 2007. FDA considerations for regulation of nanomaterial containing products. Presentation slides. www.fda.gov/…/2006-4241B1-02-31-FDA-Nano%20Sadrieh%20nanot. Accessed 4 Mar 2015.
- Salbu, B. 2016. Environmental impact and risk assessments and key factors contributing to the overall uncertainties. Journal of Environmental Radioactivity (Ahead of print).Google Scholar
- Satalkar, P., B.S. Elger, and D.M. Shaw. 2015. Defining nano, nanotechnology and nanomedicine: why should it matter? Science and Engineering Ethics (Ahead of print).Google Scholar
- Schug, T.T., A.F. Johnson, D.M. Balshaw, S. Garantziotis, N.J. Walker, C. Weis, S.S. Nadadur, and L.S. Birnbaum. 2013. ONE nano: NIEHS’s strategic initiative on the health and safety effects of engineered nanomaterials. Environmental Health Perspectives 121(4): 410–414.Google Scholar
- Seipenbusch, M., A. Binder, and G. Kasper. 2008. Temporal evolution of nanoparticle aerosols in workplace exposure. The Annals of Occupational Hygiene 52(8): 70–71.Google Scholar
- Sharma, R., N. Mody, U. Agrawal, and S.P. Vyas. 2016. Theranostic nanomedicine: a next generation platform for cancer diagnosis and therapy. Mini-Reviews in Medicinal Chemistry (Ahead of print).Google Scholar
- Siegal, G. 2015. NanoEthics and regulation. EuroNanomed II, Minutes of Consensus Meeting. Available at https://www.youtube.com/watch?v=MBJVu-g6ASo. Accessed 1 Feb 2016.
- Solbakk, J.H. 2004. Uses and abuses of biomedical research. In: Ethical eye: biomedical research. 35–50. Strasbourg Cedex: Council of Europe Publishing.Google Scholar
- The council of Canadian academies: small is different: a science perspective on the regulatory challenges of the nanoscale. http://www.scienceadvice.ca/uploads/eng/assessments%20and%20publications%20and%20news%20releases/nano/(2008_07_10)_report_on_nanotechnology.pdf.
- Transparency Market Research. http://www.transparencymarketresearch.com/pressrelease/nanomedicine-market.htm.
- UNESCO. 2005. Universal declaration on bioethics and human rights. In Adopted by UNESCO General Conference. 19 Oct.Google Scholar
- Yeagle, J. 2007. Nanotechnology and the FDA. Virginia Journal of Law and Technology 12(6): 2–20.Google Scholar